ClinicalTrials.gg

How we know

Every link on this study, and who decided it

The study on the left, the conditions and drugs this site links it to, and on each link the judgments that made or checked it, by day and by judge. The top row is the record itself: each new version seen since tracking began. Dashed lines are links the registry record does not make itself. Select a link to see everything judged on it, or a mark for one decision with its reason and evidence.

6 links0 made here, not in the record12 judgments2 judges (our rules as one)0 record changes seen
Claude Opus 5.5Our rules
Oct 19Oct 26Nov 2Nov 9Nov 16TodayNCT07256509A Study of SYS6010 CombinedWith Osimertinib VersusOsimertinib Alone asNeoadjuvant Therapy forPatients With EGFRMutation-positiveResectable Non-squamousCSPC Megalith BiopharmaceuticaPhase 2 · not yet recruitingRECORDThe record itselfVersions seen nightly since Sep 25, 2…›No new version seen since tracking began Sep 25, 2026.CONDITIONSCarcinoma, Non-Small-Cell L…The registry's MeSH filing›Nov 14 · Our condition-kind rule · Finest filed termAs of now · Our main-condition rule (R9) · Main conditionMain conditionDRUGSAnti-EGFR Antibody-drug Con…Entry “SYS6010”, read by our name rule›Nov 3 · Claude Opus 5.5 · TestedNov 18 · Our role rule · TestedTestedOsimertinibIntervention entry›Nov 3 · Claude Opus 5.5 · Background · partnerNov 18 · Our role rule · BackgroundBackground · partnerPemetrexedIntervention entry›Nov 3 · Claude Opus 5.5 · ComparatorNov 18 · Our role rule · ComparatorComparatorCisplatinIntervention entry›Nov 3 · Claude Opus 5.5 · ComparatorNov 18 · Our role rule · ComparatorComparatorCarboplatinIntervention entry›Nov 3 · Claude Opus 5.5 · ComparatorNov 18 · Our role rule · ComparatorComparator

Times are in your time zone; a day marked “day only” kept no time. The graph scrolls sideways on a narrow screen; every mark is also in the list below.

Anti-EGFR Antibody-drug Conjugate CPO301

From the registry record2 judgments on this link
Role in the study, from the registry to what was judged
RegistryEntry “SYS6010”the record gives no role
→judged=agrees
How the 2 judgments split100%of judgments with a known value say Tested
Tested · 2

All judgments on this study

WhenLinkJudgeDecisionState
Nov 3Anti-EGFR Antibody-drug Conjugate CPO301Claude Opus 5.5TestedCurrent
Nov 3OsimertinibClaude Opus 5.5Background · partnerCurrent
Nov 3PemetrexedClaude Opus 5.5ComparatorCurrent
Nov 3CisplatinClaude Opus 5.5ComparatorCurrent
Nov 3CarboplatinClaude Opus 5.5ComparatorCurrent
Nov 14Carcinoma, Non-Small-Cell LungOur condition-kind ruleFinest filed termCurrent
Nov 18Anti-EGFR Antibody-drug Conjugate CPO301Our role ruleTestedAgrees
Nov 18OsimertinibOur role ruleBackgroundAgrees
Nov 18PemetrexedOur role ruleComparatorAgrees
Nov 18CisplatinOur role ruleComparatorAgrees
Nov 18CarboplatinOur role ruleComparatorAgrees
As of nowCarcinoma, Non-Small-Cell LungOur main-condition rule (R9)Main conditionCurrent